Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage

Tanvir F. Choudhri, Brian L. Hoh, Charles J. Prestigiacomo, Judy Huang, Louis J. Kim, Ann Marie Schmidt, Walter Kisiel, E. Sander Connolly, David J. Pinsky

Research output: Contribution to journalArticle

Abstract

Agents that restore vascular patency in stroke also the risk of intracerebral hemorrhage (ICH). As Factor IXa is a key intermediary in the intrinsic pathway of coagulation, targeted inhibition of Factor IXa-dependent coagulation might inhibit microvascular thrombosis in stroke without impairing extrinsic hemostatic mechanisms that limit ICH. A competitive inhibitor of native Factor IXa for assembly into the intrinsic Factor X activation complex, Factor IXai, was prepared by covalent modification of the Factor IXa active site. In a modified cephalin clotting time assay, in vivo administrition of Factor IXai caused a dose-dependent increase in time to clot formation (3.6-fold increase at the 300 χ/kg dose compared with vehicle-treated control animals, P <0.05). Mice given Factor IXai and subjected to middle cerebral artery occlusion and reperfusion demonstrated reduced microvascular fibrin accumulation by immunoblotting and immunostaining, reduced 111In-labeled platelet deposition (42% decrease, P <0.05), increased cerebral perfusion (2.6-fold increase in ipsilateral blood flow by laser doppler, P <0.05), and smaller cerebral infarcts than vehicle- treated controls (70% reduction, P <0.05) based on triphenyl tetrazolium chloride staining of serial cerebral sections. At therapeutically effective doses, Factor IXai was not associated with increased ICH, as opposed to tissue plasminogen activator (tPA) or heparin, both of which significantly increased ICH. Factor IXai was cerebroprotective even when given after the onset of stroke, indicating that microvascular thrombosis continues to evolve (and may be inhibited) even after primary occlusion of a major cerebrovascular tributary.

Original languageEnglish (US)
Pages (from-to)91-99
Number of pages9
JournalJournal of Experimental Medicine
Volume190
Issue number1
DOIs
StatePublished - Jul 5 1999
Externally publishedYes

Fingerprint

Factor IXa
Cerebral Hemorrhage
Stroke
Wounds and Injuries
Thrombosis
Vascular Patency
Phosphatidylethanolamines
Factor X
Intrinsic Factor
Middle Cerebral Artery Infarction
Tissue Plasminogen Activator
Hemostatics
Fibrin
Immunoblotting
Reperfusion
Heparin
Chlorides
Catalytic Domain
Lasers
Blood Platelets

Keywords

  • Anticoagulation
  • Cerebral ischemia
  • Factor IX
  • Intrinsic coagulation pathway
  • Thrombosis

ASJC Scopus subject areas

  • Immunology

Cite this

Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. / Choudhri, Tanvir F.; Hoh, Brian L.; Prestigiacomo, Charles J.; Huang, Judy; Kim, Louis J.; Schmidt, Ann Marie; Kisiel, Walter; Connolly, E. Sander; Pinsky, David J.

In: Journal of Experimental Medicine, Vol. 190, No. 1, 05.07.1999, p. 91-99.

Research output: Contribution to journalArticle

Choudhri, TF, Hoh, BL, Prestigiacomo, CJ, Huang, J, Kim, LJ, Schmidt, AM, Kisiel, W, Connolly, ES & Pinsky, DJ 1999, 'Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage', Journal of Experimental Medicine, vol. 190, no. 1, pp. 91-99. https://doi.org/10.1084/jem.190.1.91
Choudhri, Tanvir F. ; Hoh, Brian L. ; Prestigiacomo, Charles J. ; Huang, Judy ; Kim, Louis J. ; Schmidt, Ann Marie ; Kisiel, Walter ; Connolly, E. Sander ; Pinsky, David J. / Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage. In: Journal of Experimental Medicine. 1999 ; Vol. 190, No. 1. pp. 91-99.
@article{f39b9e8ced4847958b0fd8c55b193751,
title = "Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage",
abstract = "Agents that restore vascular patency in stroke also the risk of intracerebral hemorrhage (ICH). As Factor IXa is a key intermediary in the intrinsic pathway of coagulation, targeted inhibition of Factor IXa-dependent coagulation might inhibit microvascular thrombosis in stroke without impairing extrinsic hemostatic mechanisms that limit ICH. A competitive inhibitor of native Factor IXa for assembly into the intrinsic Factor X activation complex, Factor IXai, was prepared by covalent modification of the Factor IXa active site. In a modified cephalin clotting time assay, in vivo administrition of Factor IXai caused a dose-dependent increase in time to clot formation (3.6-fold increase at the 300 χ/kg dose compared with vehicle-treated control animals, P <0.05). Mice given Factor IXai and subjected to middle cerebral artery occlusion and reperfusion demonstrated reduced microvascular fibrin accumulation by immunoblotting and immunostaining, reduced 111In-labeled platelet deposition (42{\%} decrease, P <0.05), increased cerebral perfusion (2.6-fold increase in ipsilateral blood flow by laser doppler, P <0.05), and smaller cerebral infarcts than vehicle- treated controls (70{\%} reduction, P <0.05) based on triphenyl tetrazolium chloride staining of serial cerebral sections. At therapeutically effective doses, Factor IXai was not associated with increased ICH, as opposed to tissue plasminogen activator (tPA) or heparin, both of which significantly increased ICH. Factor IXai was cerebroprotective even when given after the onset of stroke, indicating that microvascular thrombosis continues to evolve (and may be inhibited) even after primary occlusion of a major cerebrovascular tributary.",
keywords = "Anticoagulation, Cerebral ischemia, Factor IX, Intrinsic coagulation pathway, Thrombosis",
author = "Choudhri, {Tanvir F.} and Hoh, {Brian L.} and Prestigiacomo, {Charles J.} and Judy Huang and Kim, {Louis J.} and Schmidt, {Ann Marie} and Walter Kisiel and Connolly, {E. Sander} and Pinsky, {David J.}",
year = "1999",
month = "7",
day = "5",
doi = "10.1084/jem.190.1.91",
language = "English (US)",
volume = "190",
pages = "91--99",
journal = "Journal of Experimental Medicine",
issn = "0022-1007",
publisher = "Rockefeller University Press",
number = "1",

}

TY - JOUR

T1 - Targeted inhibition of intrinsic coagulation limits cerebral injury in stroke without increasing intracerebral hemorrhage

AU - Choudhri, Tanvir F.

AU - Hoh, Brian L.

AU - Prestigiacomo, Charles J.

AU - Huang, Judy

AU - Kim, Louis J.

AU - Schmidt, Ann Marie

AU - Kisiel, Walter

AU - Connolly, E. Sander

AU - Pinsky, David J.

PY - 1999/7/5

Y1 - 1999/7/5

N2 - Agents that restore vascular patency in stroke also the risk of intracerebral hemorrhage (ICH). As Factor IXa is a key intermediary in the intrinsic pathway of coagulation, targeted inhibition of Factor IXa-dependent coagulation might inhibit microvascular thrombosis in stroke without impairing extrinsic hemostatic mechanisms that limit ICH. A competitive inhibitor of native Factor IXa for assembly into the intrinsic Factor X activation complex, Factor IXai, was prepared by covalent modification of the Factor IXa active site. In a modified cephalin clotting time assay, in vivo administrition of Factor IXai caused a dose-dependent increase in time to clot formation (3.6-fold increase at the 300 χ/kg dose compared with vehicle-treated control animals, P <0.05). Mice given Factor IXai and subjected to middle cerebral artery occlusion and reperfusion demonstrated reduced microvascular fibrin accumulation by immunoblotting and immunostaining, reduced 111In-labeled platelet deposition (42% decrease, P <0.05), increased cerebral perfusion (2.6-fold increase in ipsilateral blood flow by laser doppler, P <0.05), and smaller cerebral infarcts than vehicle- treated controls (70% reduction, P <0.05) based on triphenyl tetrazolium chloride staining of serial cerebral sections. At therapeutically effective doses, Factor IXai was not associated with increased ICH, as opposed to tissue plasminogen activator (tPA) or heparin, both of which significantly increased ICH. Factor IXai was cerebroprotective even when given after the onset of stroke, indicating that microvascular thrombosis continues to evolve (and may be inhibited) even after primary occlusion of a major cerebrovascular tributary.

AB - Agents that restore vascular patency in stroke also the risk of intracerebral hemorrhage (ICH). As Factor IXa is a key intermediary in the intrinsic pathway of coagulation, targeted inhibition of Factor IXa-dependent coagulation might inhibit microvascular thrombosis in stroke without impairing extrinsic hemostatic mechanisms that limit ICH. A competitive inhibitor of native Factor IXa for assembly into the intrinsic Factor X activation complex, Factor IXai, was prepared by covalent modification of the Factor IXa active site. In a modified cephalin clotting time assay, in vivo administrition of Factor IXai caused a dose-dependent increase in time to clot formation (3.6-fold increase at the 300 χ/kg dose compared with vehicle-treated control animals, P <0.05). Mice given Factor IXai and subjected to middle cerebral artery occlusion and reperfusion demonstrated reduced microvascular fibrin accumulation by immunoblotting and immunostaining, reduced 111In-labeled platelet deposition (42% decrease, P <0.05), increased cerebral perfusion (2.6-fold increase in ipsilateral blood flow by laser doppler, P <0.05), and smaller cerebral infarcts than vehicle- treated controls (70% reduction, P <0.05) based on triphenyl tetrazolium chloride staining of serial cerebral sections. At therapeutically effective doses, Factor IXai was not associated with increased ICH, as opposed to tissue plasminogen activator (tPA) or heparin, both of which significantly increased ICH. Factor IXai was cerebroprotective even when given after the onset of stroke, indicating that microvascular thrombosis continues to evolve (and may be inhibited) even after primary occlusion of a major cerebrovascular tributary.

KW - Anticoagulation

KW - Cerebral ischemia

KW - Factor IX

KW - Intrinsic coagulation pathway

KW - Thrombosis

UR - http://www.scopus.com/inward/record.url?scp=0033526817&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033526817&partnerID=8YFLogxK

U2 - 10.1084/jem.190.1.91

DO - 10.1084/jem.190.1.91

M3 - Article

C2 - 10429673

AN - SCOPUS:0033526817

VL - 190

SP - 91

EP - 99

JO - Journal of Experimental Medicine

JF - Journal of Experimental Medicine

SN - 0022-1007

IS - 1

ER -